NCT03821701 is a NA clinical trial of Entresto in Chronic Heart Failure, sponsored by First Affiliated Hospital Xi'an Jiaotong University.

Who is sponsoring NCT03821701?

NCT03821701 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT03821701?

Interventions in NCT03821701: Entresto, ACEI/ARB.

What condition does NCT03821701 study?

NCT03821701 studies Chronic Heart Failure.

Is NCT03821701 still recruiting?

NCT03821701 is currently status unknown. Last updated 7 August 2019.

Last reviewed 2019-08-07 · How we verify

NCT03821701

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

Status unknown NA Last updated 7 August 2019

What this trial tests

NA trial testing Entresto in Chronic Heart Failure in 340 participants. Status unknown.

Timeline

1 June 2018

Primary endpoint
31 January 2021

31 January 2022

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	340
Start date	1 June 2018
Primary completion	31 January 2021
Estimated completion	31 January 2022
Sites	1 location across China

Drugs / interventions tested

Entresto — full drug profile →
ACEI/ARB — full drug profile →

Conditions studied

Chronic Heart Failure — all drugs for Chronic Heart Failure →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

18 and older, any sex, with Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized controlled multicenter clinical trial, in which about 340 patients with newly diagnosed or prior diagnosed chronic heart will be recruited. Patients will be randomly divided into Angiotensin-Neprilysin Inhibition (ARNI) group and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) group. All-cause death, cardiac death and re-hospitalization due to heart failure will be evaluated in 1, 3, 6, 12 months after recruitment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Entresto

Trials testing the same drug.

NCT05976230 — Special Drug Use Surveillance of Entresto Tablets (Hypertension) · completed
NCT04781881 — Special Drug Use Surveillance for Entresto Tablets · completed
NCT03553810 — Role of ARNi in Ventricular Remodeling in Hypertensive LVH · Phase 2 · completed
NCT03893526 — Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes · Phase 4 · completed
NCT03717688 — The Effects of Neprilysin on Glucagon-like Peptide-1 · Phase 4 · completed

Other recruiting trials for Chronic Heart Failure

Currently open trials in the same condition.

NCT07265349 — A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure · Phase 1, PHASE2 · recruiting
NCT07379840 — A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South K · recruiting
NCT07325942 — Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure · NA · recruiting
NCT07434193 — Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergo · NA · recruiting
NCT07405944 — Vericiguat and Reverse Remodeling Indices in Heart Failure · Phase 4 · recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03821701 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 7 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03821701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing